Le Lézard
Classified in: Health
Subjects: NPT, SVY, PSF

Kaiser Permanente Funds Firearm Injury Prevention Research Studies


OAKLAND, Calif., June 20, 2019 /PRNewswire/ -- Kaiser Permanente, the nation's largest nonprofit, integrated health system, will fund three clinical research studies that focus on how clinicians can help prevent firearm injuries ? including suicide, intimate partner violence and accidents ? as part of its pledge to invest $2 million to prevent gun injuries and deaths.

Kaiser Permanente Logo. (PRNewsFoto/Kaiser Permanente) (PRNewsfoto/Kaiser Permanente)

This initial research funding will support the following studies to be undertaken by investigators at three of Kaiser Permanente's regional research institutes in partnership with its Permanente Medical Group clinicians and physicians:

-  Evaluating a web-based education tool for safe firearm storage in patients at risk for suicide ? Kaiser Permanente Colorado Institute for Health Research.
-  Understanding risk factors of firearm-related injuries and death in adult and pediatric populations: Risk prediction and opportunities for prevention ? Kaiser Permanente Southern California Department of Research and Evaluation.
-  Integration of firearm suicide-prevention tools in health care settings: Patient-reported access to firearms and decision aid for storing firearms ? Kaiser Permanente Washington Health Research Institute.

"We believe that safety is integral to the health and well-being of individuals and communities. People need to be safe in the places where they live, work, learn and play," said Bernard J. Tyson, chairman and CEO, Kaiser Permanente. "We know that firearm injury is a leading cause of preventable death in the U.S., and we can leverage our research capabilities combined with our deep clinical experience to help tackle this issue."

In 2018, Kaiser Permanente announced the formation of its Firearm Injury Prevention Task Force and an accompanying $2 million research fund to address preventable gun-related injuries and death. The initiative's goal is to understand what the best practices currently are, to investigate new ones and to standardize practices that are grounded in evidence and show demonstrated effectiveness.

"The best-in-class care Kaiser Permanente provides is accomplished, in part, by our use of rigorous research to determine which strategies are effective," said David Grossman, MD MPH, senior associate medical director with the Washington Permanente Medical Group and co-chair of the Firearm Injury Prevention Task Force. "This funding is an initial down payment on tackling a critical issue, and we hope our firearm research program will serve as a model and catalyze future efforts to close the research gaps that exist."

Each of the 24-month studies will focus on groups considered to be high risk for either intentional or unintentional firearm injuries. In line with Kaiser Permanente's commitment to making best practices and research learnings accessible across the health care industry, the findings of these studies will be submitted for publication in peer-reviewed journals.

"This announcement is a key step in our long-term commitment to address gun-related injury and death in our communities, and the resulting research will provide important guides to be used throughout the health care sector for clinical firearm injury prevention," said Bechara Choucair, MD, senior vice president, chief community health officer at Kaiser Permanente, and co-chair of the Firearm Injury Prevention Task Force. "With more than 68 million people living in Kaiser Permanente's communities, it is our responsibility to bring together health leaders and clinical care providers to help solve this public health challenge and, ultimately, save lives."

About Kaiser Permanente
Kaiser Permanente is committed to helping shape the future of health care. We are recognized as one of America's leading health care providers and not-for-profit health plans. Founded in 1945, Kaiser Permanente has a mission to provide high-quality, affordable health care services and to improve the health of our members and the communities we serve. We currently serve 12.3 million members in eight states and the District of Columbia. Care for members and patients is focused on their total health and guided by their personal Permanente Medical Group physicians, specialists and team of caregivers. Our expert and caring medical teams are empowered and supported by industry-leading technology advances and tools for health promotion, disease prevention, state-of-the-art care delivery and world-class chronic disease management. Kaiser Permanente is dedicated to care innovations, clinical research, health education and the support of community health. https://about.kaiserpermanente.org/

For more information, contact:
Marc Brown, [email protected], 510-271-6328

 

SOURCE Kaiser Permanente


These press releases may also interest you

at 08:40
PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") , a biotechnology company focused on the research, development, and manufacturing of LaNeotm MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that, further...

at 08:33
Prescient Healthcare Group, a leading biopharma product and portfolio strategy firm, has announced the appointment of two new members to its Board of Directors ? Dr. Luke Solon and Debbie Allman ? to help shape and drive Prescient's global mission....

at 08:31
Snufff, the innovative nasal inhaler, emerges onto the wellness and lifestyle scene, offering a refreshing blend of enjoyment and health benefits. Crafted in the vibrant heart of Singapore, Snufff aims to revolutionize the way we approach personal...

at 08:31
Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") , a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that it filed its annual report on Form 20-F for the...

at 08:15
MGI Tech, a company committed to building core tools and technology to lead life science, is proud to announce that its DNBSEQ-T20x2* gene sequencer has been recognized with a Gold Edison Award in the "Health, Medical & Biotech" category....

at 08:05
Antibe Therapeutics Inc. ("Antibe" or the "Company") announced that the Company sought an extension of its previously announced stay of proceedings ("Stay") under the Companies' Creditors Arrangement Act (the "CCAA") at a hearing before the Ontario...



News published on and distributed by: